Psoriasis

Healio rounded up psoriasis coverage and expert analysis presented and discussed at Maui Derm for Dermatologists in Wailea, Hawaii.

Treatment with Siliq may lead to long-term skin clearance among patients with psoriasis who require an option following prior therapeutic avenues, according to a study published in the Journal of Drugs in Dermatology.

Twice-weekly maintenance doses of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam with Otezla proved to be an effective combination treatment for psoriasis, according to data published in the Journal of Drugs in Dermatology.

Researchers found that higher BMI appears to correlate with an increased risk for developing psoriasis, regardless of age, sex, race and smoking status, according to data published in the Journal of the American Academy of Dermatology.

While biologic therapy persistence rates were generally low at 3 years, interleukin-17 inhibitors were generally more persistent than tumor necrosis factor inhibitors in both psoriasis and psoriatic arthritis, according to a study.

Addictions to smoking, alcohol and the internet were common in patients with psoriasis, according to a study.

BOSTON — Psoriasis patients treated with apremilast saw a reduction in subcutaneous and visceral fat, indicating a possible decline in cardiometabolic risk, according to a presentation at the American Academy of Dermatology Annual Meeting.

Plaque psoriasis patients who had residual plaques following ixekizumab saw success with adjunctive calcipotriene 0.005%/betamethasone dipropionate 0.064% foam, according to a study.

Early response to ixekizumab or ustekinumab was associated with stable, long-term response in moderate to severe psoriasis, according to a study.

Epicardial adipose tissue volumes were greater in men with psoriasis compared with controls, according to a study.